CD33 and acute myeloid leukemia: In a study in a mainly pediatric population, but also including young adults (COG-AAML0531) with AML (0-29 years old), a benefit of GO was demonstrated in the induction treatment in those with CC genotype of CD33 rs12459419 polymorphism [12].